On November 9, 2026 Qureator, a leading techbio company delivering regulatory-grade translational data through its vTIME 3D human tissue platform, reported preclinical data evaluating the dual pharmacology of a PD-1xVEGF bispecific antibody and the vascular safety profile of a T-cell engager in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Developing effective cancer therapies requires a deeper understanding of how treatments interact with the complex tumor microenvironment, yet traditional preclinical models often fall short of capturing these critical interactions," said Kyu Baek, Ph.D., chief executive officer of Qureator. "These findings highlight the unique capabilities of our AI-powered vTIME model to simultaneously evaluate vascular and immune responses within a fully human, patient-relevant system, while capturing translational safety and efficacy benchmarks. By providing a more comprehensive understanding of how cancer therapies behave in human tissue systems, we believe our vTIME platform has the potential to bridge critical gaps in preclinical research, reduce development risks, and ultimately accelerate the delivery of more effective treatments to patients."
Junfeng Wang, M.D., Ph.D., principal scientist and presenter of the poster, added, "We specifically tested our model with two of the most promising modalities in oncology, PD-1xVEGF bispecific antibodies and T-cell engagers. We were pleased to find the results provide clear mechanistic validation of its impact on human tumor cells, immune cells, and perfused human vessels, with particular insights into the therapeutic window between efficacy and CRS. The findings support vTIME as a physiologically relevant human tumor model for immune-oncology, which we believe provides essential translational insights to optimize therapeutic dosing and reduce clinical risk."
To address the translational gap that exists in oncology drug discovery and development today, Qureator developed vTIME, which incorporates perfusable blood vessels, stromal cells, and patient-derived cancer organoids that preserve tumor heterogeneity and genetic mutations. New data presented demonstrate the model’s ability to simultaneously evaluate vascular and immune responses to therapeutic interventions, including dose-dependent changes in vessel pruning, endothelial activation, T-cell infiltration, and anti-tumor immunity. Additionally, the model resolved distinct biphasic cytokine dynamics (IFN- and IL-6) and endothelial damage associated with CRS (Cytokine Release Syndrome), while demonstrating that co-administration of anti-IL-6R protected the microvasculature without blunting anti-tumor cytotoxicity. Together, these findings support the potential of the platform to provide a more physiologically relevant approach to preclinical oncology research, helping to inform therapeutic development and reduce translational risks.
All posters are available on the SITC (Free SITC Whitepaper) virtual meeting platform.
(Press release, Qureator, NOV 9, 2026, View Source [SID1234674514])